|Day Low/High||4.35 / 4.65|
|52 Wk Low/High||2.93 / 4.62|
Enzyme developed with CodeEvolver® technology for preclinical therapeutics program exceeds agreement requirements
Codexis, Inc. (Nasdaq: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the filing of a lawsuit against EnzymeWorks and its founder, Junhua "Alex" Tao, for willful...
Stocks with insider trader activity include CDXS, KN and CNBKA
Stocks with insider trader activity include WTS, CDXS and CHMI
First Significant Agreement for Development of Novel Enzyme for Biologics Drug Development
While we await an interest rate hike, we check out the effects of the earnings parade on our portfolio.